Adam Townsend - Apellis Pharmaceuticals Chief Commercial Officer
| APLS Stock | USD 27.75 0.26 0.95% |
Executive
Mr. Adam J. Townsend is Chief Commercial Officer of the Company. From March 2010 to October 2018 he served in a variety of leadership roles at Biogen, including as Senior Vice President of Corporationrationrate Development from March 2018 to October 2018, as Senior Vice President, Specialty Medicines and Rare Disease Group from April 2017 to March 2018, as Vice President, Asset Executive for Spinraza from May 2016 to April 2017, Vice President Account Executive for Hemophilia from November 2015 to May 2016, and Vice President Global Marketing Head of Multiple Sclerosis from July 2013 to November 2015. Mr. Townsend received his medical biochemistry degree from Royal Holloway, University of London. since 2018.
| Age | 46 |
| Tenure | 6 years |
| Address | 100 Fifth Avenue, Waltham, MA, United States, 02451 |
| Phone | 617 977 5700 |
| Web | https://www.apellis.com |
Apellis Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1623) % which means that it has lost $0.1623 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0656) %, meaning that it created substantial loss on money invested by shareholders. Apellis Pharmaceuticals' management efficiency ratios could be used to measure how well Apellis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.7 in 2024. Return On Capital Employed is likely to drop to -1 in 2024. At this time, Apellis Pharmaceuticals' Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 205.1 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 18.2 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Diana Chung | Terns Pharmaceuticals | N/A | |
| Alex Howarth | Madrigal Pharmaceuticals | 55 | |
| Thomas Hare | Madrigal Pharmaceuticals | N/A | |
| Lauren MBA | Immunovant | N/A | |
| Christine Blodgett | Immunovant | N/A | |
| Adam JD | Day One Biopharmaceuticals | 57 | |
| Brian JD | Madrigal Pharmaceuticals | 62 | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| Lindsey Allen | Amylyx Pharmaceuticals | N/A | |
| Michael CPA | Blueprint Medicines Corp | 52 | |
| JD Esq | Acumen Pharmaceuticals | 53 | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Julian Baker | Blueprint Medicines Corp | 57 | |
| PharmD MBA | Madrigal Pharmaceuticals | N/A | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| Kathryn Haviland | Blueprint Medicines Corp | 48 | |
| Camille MD | Amylyx Pharmaceuticals | 71 | |
| Edward Chiang | Madrigal Pharmaceuticals | N/A | |
| Mark Underwood | Madrigal Pharmaceuticals | N/A | |
| Catriona Yale | Akero Therapeutics | 52 | |
Management Performance
| Return On Equity | -1.07 | ||||
| Return On Asset | -0.16 |
Apellis Pharmaceuticals Leadership Team
Elected by the shareholders, the Apellis Pharmaceuticals' board of directors comprises two types of representatives: Apellis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Apellis. The board's role is to monitor Apellis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Apellis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Apellis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Sullivan, CFO, Treasurer | ||
| Cedric MD, President, CoFounder | ||
| Meredith Kaya, Investor President | ||
| Adam Townsend, Chief Commercial Officer | ||
| James CPA, Corporate VP | ||
| Karen Lewis, Chief Officer | ||
| Nur Nicholson, Chief Officer | ||
| JD Esq, General Counsel | ||
| MBA JD, CoFounder Director | ||
| Pr MD, Head Board | ||
| David Acheson, Senior Commercial | ||
| Lukas MD, Chief Officer | ||
| Mark Delong, Chief Officer | ||
| Federico MD, CoFounder Officer | ||
| Victoria Brown, Senior President | ||
| Pascal Deschatelets, CoFounder Officer | ||
| Caroline MD, Chief Officer | ||
| Jeffrey Eisele, Chief Officer |
Apellis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Apellis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.07 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.35) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 3.68 B | ||||
| Shares Outstanding | 124.39 M | ||||
| Shares Owned By Insiders | 13.98 % | ||||
| Shares Owned By Institutions | 97.44 % | ||||
| Number Of Shares Shorted | 20.79 M | ||||
| Price To Earning | (6.94) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.